Gratry & Company’s Pfizer PFE Stock Holding History

Gratry & Company’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,420	Closed	-$229K	–	86
2016 Q4	$229K	Sell	7,420 -922	-11%	-$28.1K	0.2%	72
2016 Q3	$268K	Buy	+8,342	New	+$279K	0.21%	59

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Gratry & Company's PFE Position: Q1 2017 in Review

Gratry & Company sold out of Pfizer (PFE) in Q1 2017, closing a stake of 7,420 shares — an estimated $229K sold.

Gratry & Company first reported a position in PFE in Q3 2016 and held it in 2 quarters. The position peaked at $268K in Q3 2016. 2,074 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Gratry & Company reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
Gratry & Company sold 7,420 Pfizer shares in Q1 2017, an estimated $229K.
Gratry & Company first reported a position in Pfizer in Q3 2016 and held it in 2 quarters.
Gratry & Company's Pfizer position peaked at $268K in Q3 2016.
2,074 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Gratry & Company's 13F filing for Q1 2017, filed 4 May 2017.